AbbVie shares rose 2.1% this morning to a price of $238.04. The stock is still trading within range of its average target price of $241.72, and over the last 52 weeks, it has recorded a 37.5% performance. Analysts have given the Large-Cap Pharmaceutical stock target prices ranging from $184.0 to $289.0 dollars per share, with an average rating of buy.
AbbVie's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 1.1%. The stock's short ratio is 3.09. At 0.1%, the company's rate of insider ownership does not indicate that management is heavily invested in the corporation.
Another number to watch is the company's rate of institutional share ownership, which now stands at 74.5%. In conclusion, we believe there is mixed market sentiment regarding AbbVie.
Institutions Invested in AbbVie
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-09-30 | Vanguard Group Inc | 10% | 177,747,261 | $42,310,956,815 |
| 2025-09-30 | Blackrock Inc. | 8% | 145,977,089 | $34,748,385,285 |
| 2025-06-30 | State Street Corporation | 5% | 80,024,129 | $19,048,943,129 |
| 2025-09-30 | JPMORGAN CHASE & CO | 3% | 56,534,816 | $13,457,547,221 |
| 2025-06-30 | Morgan Stanley | 2% | 41,700,001 | $9,926,267,958 |
| 2025-09-30 | Geode Capital Management, LLC | 2% | 40,439,493 | $9,626,216,642 |
| 2025-09-30 | Charles Schwab Investment Management, Inc. | 1% | 25,958,106 | $6,179,067,377 |
| 2025-06-30 | Capital Research Global Investors | 1% | 25,265,579 | $6,014,218,255 |
| 2025-06-30 | Bank of America Corporation | 1% | 25,109,645 | $5,977,099,727 |
| 2025-06-30 | NORGES BANK | 1% | 23,102,037 | $5,499,208,732 |
